CANC vs IDNA
Tema Oncology ETF against iShares Genomics Immunology and Healthcare ETF: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
24%
15 shared positions
Fee gap
28 bp
IDNA is cheaper
1-year return gap
32.8 pts
IDNA is ahead
Larger fund
IDNA
$325M
Side by side
| CANC | IDNA | |
|---|---|---|
| Fund | Tema Oncology ETF | iShares Genomics Immunology and Healthcare ETF |
| Issuer | Tema | iShares |
| Category | Biotech & Health Innovation | Biotech & Health Innovation |
| Expense ratio | 0.75% | 0.47% |
| Assets | $176M | $325M |
| Average daily dollar volume | $1.2M | $7.6M |
| Listed | Aug 14, 2023 | Jun 11, 2019 |
| FrenzyCap score | 36 | 60 |
| 1-month return | −3.0% | +2.3% |
| 3-month return | +0.5% | +32.0% |
| Year to date | +19.6% | +63.0% |
| 1-year return | +36.3% | +69.0% |
| 30-day volatility | 26.2% | 33.5% |
| Worst drawdown, 1 year | −13.2% | −10.7% |
| Trailing 12-month yield | 0.05% | 0.66% |
| Holdings | 61 | 63 |
| Top 10 weight | 40.0% | 50.1% |
| Look-through P/E | — | — |
| Holdings vs fair value | +6.0% | +1.6% |
| Holdings above 200-day average | 67% | 86% |
| Net flow, latest 3 reported months | +$14M thru May 2026 | +$15M thru Jul 2026 |
| 30-day implied volatility | — | 33.2% |
| Holdings as of | as of Oct 1, 2026third-party data | as of Oct 20, 2026issuer data |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
29% of CANC · 48% of IDNA
Sector mix of the stock holdings
| Sector | CANC | IDNA | Gap |
|---|---|---|---|
| Health Care | 92.6% | 80.3% | +12.3% |
| Technology | 0.0% | 0.5% | −0.5% |
More: full overlap table · CANC holdings · IDNA holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.